Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding by Zhe Yu, Ling Gao, Yinshan Zang, Lu Cheng, Wenjia Gao, Yan Xu

Get full text

Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model by Lei Wang, Chengyin Lv, Hanxiao You, Lingxiao Xu, Fenghong Yuan, Ju Li, Min Wu, Shiliang Zhou, Zhanyun Da, Jie Qian, Hua Wei, Wei Yan, Lei Zhou, Yan Wang, Songlou Yin, Dongmei Zhou, Jian Wu, Yan Lu, Dinglei Su, Zhichun Liu, Lin Liu, Longxin Ma, Xiaoyan Xu, Yinshan Zang, Huijie Liu, Tianli Ren, Jin Liu, Fang Wang, Miaojia Zhang, Wenfeng Tan

Get full text